Malaria control is seriously limited in Africa by the increasing resistance of parasites to available drugs. Important needs are the characterization of drug resistance and the assessment of the comparative efficacy of available drugs. These goals require skilled personnel and a complex infrastructure for research. This proposal describes a training program for Uganda that builds on a collaboration between UCSF and Makerere University that began in 1998, has engaged Ugandan and American trainees, and has established a productive center for clinical malaria research in Kampala. The principal goal of this project will be to train Ugandans in modern methods of clinical, epidemiological, and molecular research in Uganda. These are broad objectives, but they will be pursued in a focused manner, with all research activities directed toward the evaluation of anti-malarial drug efficacy and resistance in Kampala. For all activities, trainees will receive one-on-one mentoring from project faculty and appropriate coursework. In some cases, activities may lead to degree-granting programs in epidemiology or biochemistry.
Specific aims of the project will be follows. a. Training Ugandan investigators in clinical malaria research. Trainees will participate in ongoing projects in Kampala assessing and comparing the anti-malarial efficacy of available and experimental drugs. b. Training Ugandan investigators in epidemiologic methods relevant to the study of anti-malarial drug resistance. Trainees will link core studies at either Makerere University or the University of California (UCSF and UC Berkeley) with evaluations of the epidemiology of anti-malarial drug resistance in Kampala. c. Training Ugandan investigators in methods of molecular parasitology research pertinent to the study of anti-malarial drug resistance. Trainees will take part in laboratory research activities at molecular parasitology laboratories at Makerere University and at UCSF that are directed toward the elucidation of mechanisms of anti-malarial drug resistance and are appropriate for the developing country setting.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
International Research Training Grants (D43)
Project #
5D43TW001506-02
Application #
6395013
Study Section
Special Emphasis Panel (ZAI1-ALR-F (S4))
Program Officer
Sina, Barbara J
Project Start
2000-09-29
Project End
2005-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$150,000
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Gantt, Soren; Huang, Meei-Li; Magaret, Amalia et al. (2013) An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 58:276-8
Baliraine, Frederick N; Nsobya, Samuel L; Achan, Jane et al. (2011) Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in Uganda. Antimicrob Agents Chemother 55:615-22
Nsobya, Samuel L; Kiggundu, Moses; Nanyunja, Sarah et al. (2010) In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother 54:1200-6
Nawaz, Fatima; Nsobya, Samuel L; Kiggundu, Moses et al. (2009) Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J Infect Dis 200:1650-7
Zongo, Issaka; Dorsey, Grant; Rouamba, Noel et al. (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369:491-8
Dokomajilar, Christian; Lankoande, Zambende Moise; Dorsey, Grant et al. (2006) Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg 75:162-5
Zongo, Issaka; Dorsey, Grant; Rouamba, Noel et al. (2005) Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg 73:826-32